Biopharma Company Seeks Post-Grant Review Of Interfering RNA Patent
ALEXANDRIA, Va. — A claimed form of synthetically interfering ribonucleic acid (RNAi) molecules is not entitled to patent protection, Alnylam Pharmaceuticals Inc. asserts in a June 11 petition for post-grant review...To view the full article, register now.
Already a subscriber? Click here to view full article